Streetbeat News

Revenues

MASI

Analysts have updated their ratings and price targets for Masimo (NASDAQ:MASI), showing a mix of bullish and indifferent stances. The average 12-month price target has been raised to $142.4, indicating a 26.24% increase from the previous target. Despite the positive analyst outlook, Masimo faces challenges such as a decline in revenue, below-average net margin, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 6:01 pm

ALL

Analysts have provided diverse opinions on Allstate (NYSE:ALL) with 13 recent ratings ranging from bullish to bearish. The average 12-month price target for ALL has increased by 16.64% to $172.31. Analysts from firms like Goldman Sachs, UBS, and Wells Fargo have adjusted their ratings and price targets, reflecting a positive outlook on Allstate's performance despite challenges in revenue growth, net margin, and debt management. Allstate's market capitalization and ROE stand out positively in the industry.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 6:00 pm

SPG

Simon Property Group (NYSE:SPG) received mixed analyst ratings over the past three months, with all five recent ratings being indifferent. The average 12-month price target for SPG has been raised to $145.6, reflecting a 5.35% increase from the previous target. Analysts from Truist Securities, Evercore ISI Group, and Morgan Stanley have raised their price targets, indicating a positive outlook on SPG's financial performance, which includes a notable revenue growth rate of 9.11% and a high net margin of 48.94%. However, the company's high debt-to-equity ratio of 8.89 poses a financial risk.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 6:00 pm

CHWY

Chewy Inc (NYSE:CHWY) shares dropped 5.8% to $15.66 after issuing Q1 net sales guidance below estimates, despite reporting positive Q4 earnings growth. The company's net sales for the fiscal year increased by 10.2% year-over-year. Chewy's stock has declined by 55.16% over the past year, with a 52-week high of $40.78 and a low of $15.23.

Portfolio Pulse from Henry Khederian

March 25, 2024 | 5:07 pm

GPRE

Green Plains (NASDAQ:GPRE) has been analyzed by 4 analysts, showing a unanimous bullish stance with a recent average price target of $38.75, up 3.33% from the previous $37.50. Analysts from Roth MKM, UBS, Goldman Sachs, and Truist Securities have adjusted their price targets, reflecting dynamic market conditions and company performance. Despite a negative revenue trend and challenges in asset utilization, Green Plains exhibits strong profitability with an exceptional net margin and ROE, but faces constraints in market capitalization and growth expectations.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 5:01 pm

BRX

Recent analyst ratings for Brixmor Property Group (NYSE:BRX) show a mix of bullish and indifferent sentiments, with an updated average 12-month price target of $24.00, reflecting a 5.77% increase from the previous target. The company, a US-based REIT with a portfolio of grocery-anchored shopping centers, has seen varied financial performance, including below-industry average market capitalization and net margin, but notable revenue growth and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 5:00 pm

ROIV

Roivant Sciences (NASDAQ:ROIV) has received mixed analyst ratings in the past three months, with a total of 5 analysts offering their perspectives. The ratings include 2 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target for ROIV has been updated to $17.8, up from $14.50, indicating a 22.76% increase. Analysts from firms such as Truist Securities, Wolfe Research, HC Wainwright & Co., Piper Sandler, and B of A Securities have provided updates, with actions ranging from maintaining to raising and lowering their ratings and price targets. Roivant Sciences, a biopharmaceutical company, has shown impressive financial performance with a revenue growth rate of 117.8%, a net margin of 13721.55%, and ROE of 144.81%.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 5:00 pm

BIIB

18 analysts have shared diverse evaluations of Biogen (NASDAQ:BIIB) over the last three months, with sentiments ranging from bullish to bearish. The average 12-month price target for BIIB is now $302.44, down from the previous $320.36, indicating a negative sentiment shift. Analysts have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market position. Biogen's financials show challenges in revenue growth, net margin, ROE, and ROA, suggesting potential difficulties ahead.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 5:00 pm

CLH

Five analysts have recently shared their views on Clean Harbors (NYSE:CLH), showing a positive shift in sentiment with an average 12-month price target of $203.2, reflecting an 8.09% increase from the previous target of $188.00. The company's financial performance is strong, with a notable revenue growth rate of 4.7%, a net margin of 7.35%, and an ROE of 4.44%. Clean Harbors is recognized for its effective cost management and profitability, with a debt-to-equity ratio of 1.11 indicating a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:08 pm

KLAC

21 analysts have recently shared their evaluations of KLA (NASDAQ:KLAC), showing a mix of bullish and bearish perspectives. The average 12-month price target for KLA is now $657.38, reflecting a 9.99% increase from the previous target. Analysts' ratings range from 'Buy' to 'Underweight', with several firms adjusting their price targets upwards. KLA, a leading semiconductor equipment manufacturer, faces revenue challenges with a -16.66% decline over 3 months but maintains strong profitability indicators such as a net margin of 23.43% and ROE of 19.31%. The company's debt-to-equity ratio is higher than the industry average, indicating financial risk.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:07 pm